Author:
Li Yiming,Shao Wenxin,Wang Xingwen,Geng Kuo,Wang Wenhui,Liu Zhiwei,Chen Youjun,Shen Chaozhuang,Xie Haitang
Reference59 articles.
1. Epilepsy in adults;Thijs;Lancet,2019
2. Brivaracetam: First Global Approval;Markham;Drugs,2016
3. FDA. U.S. Food and Drug Administration. Label-BRIVIACT®(brivaracetam). Available at: https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/387905. Accessed May 24, 2023. .
4. EMA. European Medicines Agency. Label-BRIVIACT®(in Italy: Nubriveo). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo. Accessed January 10, 2024. .
5. Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations;de Biase;Expert Opin Drug Metab Toxicol,2020